Angiotensin Receptor

Angiotensin Receptor Products

  • All (20)
  • Angiotensin Receptor Inhibitor (1)
  • Angiotensin Receptor Antagonists (19)
  • New Angiotensin Receptor Products
Catalog No. Product Name Information Product Use Citations Product Validations
S5067 Losartan Losartan(DuP-753) is a selective, orally administered, nonpeptide blocker of angiotensin II type 1 (AT1) receptor used to treat high blood pressure, diabetic kidney disease, heart failure, and left ventricular enlargement.
Proc Natl Acad Sci U S A, 2023, 120(6):e2219199120
Cell Death Discov, 2022, 8(1):134
Front Pharmacol, 2021, 12:765951
S1578 Candesartan Candesartan is an angiotensin II receptor antagonist with IC50 of 0.26 nM.
Front Pharmacol, 2022, 13:828643
Hypertension, 2021, 77(5):1723-1736
Front Physiol, 2020-, Volume 11
S7098 PD123319 PD 123319 is a potent, selective AT2 angiotensin II receptor antagonist with IC50 of 34 nM.
Cell Res, 2021, 10.1038/s41422-020-00464-8
Int J Biochem Cell Biol, 2020, 121:105703
Neurosci Lett, 2020, 716:134684
S1359 Losartan Potassium Losartan Potassium is an angiotensin II receptor antagonist, competes with the binding of angiotensin II to AT1 receptors with IC50 of 20 nM.
Int J Mol Sci, 2023, 24(4)3564
Drug Deliv Transl Res, 2023, 10.1007/s13346-023-01413-9
Adv Healthc Mater, 2021, e2001856
S7678 Sacubitril/valsartan (LCZ696) Sacubitril/valsartan (LCZ696, Sacubitril, Valsartan), consisting of valsartan and sacubitril in 1:1 molar ratio, is an orally bioavailable, dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) for hypertension and heart failure. Phase 3.
Biomed Pharmacother, 2023, 162:114569
Oxid Med Cell Longev, 2022, 2022:5009289
Oxid Med Cell Longev, 2022, 2022:5009289
S1738 Telmisartan Telmisartan (BIBR 277) is an angiotensin II receptor antagonist (ARB) used in the management of hypertension.
Exp Ther Med, 2022, 23(3):216
Cell Mol Gastroenterol Hepatol, 2021, S2352-345X(21)00196-X
Eur J Pharmacol, 2021, S0014-2999(21)00845-1
S1507 Irbesartan Irbesartan (BMS-186295, SR-47436,APROVEL) is a highly potent and specific angiotensin II type 1 (AT1) receptor antagonist with IC50 of 1.3 nM.
Xenobiotica, 2020, 10.1080/00498254.2020.1745318
Front Physiol, 2019, 10:681
Antiviral Res, 2015, 120:140-6
S1894 Valsartan Valsartan is a selective angiotensin II receptor antagonist, used to treat high blood pressure and congestive heart failure.
Arch Toxicol, 2022, 96(4):1065-1074
Int J Mol Sci, 2021, 22(16)8598
Sci Rep, 2015, 5:8116
S2037 Candesartan Cilexetil Candesartan Cilexetil (TCV-116) is an angiotensin II receptor antagonist with IC50 of 0.26 nM, used in the treatment of hypertension.
Int J Mol Sci, 2022, 23(20)12326
Sci Rep, 2015, 5:8116
Exp Biol Med, 2015, 10.1177/1535370215576312
S8695 ML221 ML221 is a potent apelin receptor (APJ) functional antagonist in cell-based assays that is >37-fold selective over the closely related angiotensin II type 1 (AT1) receptor. The IC50 values of ML221 are 0.70 and 1.75 μM in a cAMP assay and β-arrestin assay, respectively.
Nat Commun, 2022, 13(1):4229
Nat Commun, 2022, 13(1):4229
J Mol Cell Cardiol, 2021, S0022-2828(21)00246-7
S4102 Eprosartan Mesylate Eprosartan(SKF-108566J) is a nonpeptide angiotensin II receptor antagonist, [3H]-eprosartan binds to the AT1 receptor with KD of 0.83 nM in rat vascular smooth muscle cells.
Eur J Drug Metab Pharmacokinet, 2022, 10.1007/s13318-022-00780-x
bioRxiv, 2020, 10.1101/2020.10.13.337774
Sci Rep, 2016, 10.1038/srep25694
S3046 Azilsartan Azilsartan (TAK-536) is an angiotensin II type 1 (AT1) receptor antagonist with IC50 of 2.6 nM.
Front Pharmacol, 2021, 12:774709
bioRxiv, 2020, 10.1101/2020.10.13.337774
Sci Rep, 2015, 5:8116
S1604 Olmesartan Medoxomil Olmesartan Medoxomil (CS-866,RNH-6270) is a selective angiotensin II type 1 (AT(1)) receptor antagonist, used in the treatment of high blood pressure.
Nan Fang Yi Ke Da Xue Xue Bao, 2020, 40(4):499-505
Sci Rep, 2015, 5:8116
S6665 Sparsentan (PS-433540, RE-021) Sparsentan (PS-433540, RE-021, DARA) is a dual endothelin type A receptor(ETA) and angiotensin II type 1 receptor antagonist.
Front Pharmacol, 2022, 13:964370
Biomedicines, 2021, 10(1)86
E0039 A-779

A-779 is a potent and selective antagonist for Angiotensin-(1–7) (Ang-(1-7)) with an IC50 of 0.3 nM in a radioligand binding assay. A-779 shows no significant affinity for AT1 or AT2 receptors at a concentration of 1 μM.

Int J Biol Sci, 2023, 19(8):2613-2629
Elife, 2022, 11e72266
S3057 Azilsartan Medoxomil Azilsartan Medoxomil (TAK-491) is a potent angiotensin II type 1 (AT1) receptor antagonist, inhibits the RAAS, with an IC50 of 2.6 nM, exhibits >10,000-fold selectivity over AT2.
Sci Rep, 2015, 5:8116
S5581 Olmesartan Olmesartan (RNH-6270) is an an angiotensin 2 receptor antagonist with antihypertensive activity.
bioRxiv, 2020, 10.1101/2020.10.13.337774
S4975 Fimasartan Fimasartan (Kanarb) is a non-peptide angiotensin II receptor antagonist (ARB) with noncompetitive, insurmountable binding with the AT1 receptor. It is used for the treatment of hypertension and heart failure.
Drug Metab Dispos, 2020, 48(12):1264-1270
S0326 Olodanrigan (EMA401) Olodanrigan (EMA401, PD-126055, (S) PD-126055) is a highly selective, orally active, peripherally restricted antagonist of angiotensin II type 2 receptor (AT2R). Olodanrigan (EMA401) analgesic action appears to involve the inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons.
S5980 Losartan Carboxylic Acid (EXP-3174) Losartan Carboxylic Acid (E-3174, EXP-3174), an active carboxylic acid metabolite of Losartan, is a non-peptide angiotensin II (AT1) receptor antagonist. Losartan Carboxylic Acid inhibits the specific binding of [125I]-angiotensin II to VSMC with IC50 of 1.1 nM.
S7678 Sacubitril/valsartan (LCZ696) Sacubitril/valsartan (LCZ696, Sacubitril, Valsartan), consisting of valsartan and sacubitril in 1:1 molar ratio, is an orally bioavailable, dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) for hypertension and heart failure. Phase 3.
Biomed Pharmacother, 2023, 162:114569
Oxid Med Cell Longev, 2022, 2022:5009289
Oxid Med Cell Longev, 2022, 2022:5009289
S5067 Losartan Losartan(DuP-753) is a selective, orally administered, nonpeptide blocker of angiotensin II type 1 (AT1) receptor used to treat high blood pressure, diabetic kidney disease, heart failure, and left ventricular enlargement.
Proc Natl Acad Sci U S A, 2023, 120(6):e2219199120
Cell Death Discov, 2022, 8(1):134
Front Pharmacol, 2021, 12:765951
S1578 Candesartan Candesartan is an angiotensin II receptor antagonist with IC50 of 0.26 nM.
Front Pharmacol, 2022, 13:828643
Hypertension, 2021, 77(5):1723-1736
Front Physiol, 2020-, Volume 11
S7098 PD123319 PD 123319 is a potent, selective AT2 angiotensin II receptor antagonist with IC50 of 34 nM.
Cell Res, 2021, 10.1038/s41422-020-00464-8
Int J Biochem Cell Biol, 2020, 121:105703
Neurosci Lett, 2020, 716:134684
S1359 Losartan Potassium Losartan Potassium is an angiotensin II receptor antagonist, competes with the binding of angiotensin II to AT1 receptors with IC50 of 20 nM.
Int J Mol Sci, 2023, 24(4)3564
Drug Deliv Transl Res, 2023, 10.1007/s13346-023-01413-9
Adv Healthc Mater, 2021, e2001856
S1738 Telmisartan Telmisartan (BIBR 277) is an angiotensin II receptor antagonist (ARB) used in the management of hypertension.
Exp Ther Med, 2022, 23(3):216
Cell Mol Gastroenterol Hepatol, 2021, S2352-345X(21)00196-X
Eur J Pharmacol, 2021, S0014-2999(21)00845-1
S1507 Irbesartan Irbesartan (BMS-186295, SR-47436,APROVEL) is a highly potent and specific angiotensin II type 1 (AT1) receptor antagonist with IC50 of 1.3 nM.
Xenobiotica, 2020, 10.1080/00498254.2020.1745318
Front Physiol, 2019, 10:681
Antiviral Res, 2015, 120:140-6
S1894 Valsartan Valsartan is a selective angiotensin II receptor antagonist, used to treat high blood pressure and congestive heart failure.
Arch Toxicol, 2022, 96(4):1065-1074
Int J Mol Sci, 2021, 22(16)8598
Sci Rep, 2015, 5:8116
S2037 Candesartan Cilexetil Candesartan Cilexetil (TCV-116) is an angiotensin II receptor antagonist with IC50 of 0.26 nM, used in the treatment of hypertension.
Int J Mol Sci, 2022, 23(20)12326
Sci Rep, 2015, 5:8116
Exp Biol Med, 2015, 10.1177/1535370215576312
S8695 ML221 ML221 is a potent apelin receptor (APJ) functional antagonist in cell-based assays that is >37-fold selective over the closely related angiotensin II type 1 (AT1) receptor. The IC50 values of ML221 are 0.70 and 1.75 μM in a cAMP assay and β-arrestin assay, respectively.
Nat Commun, 2022, 13(1):4229
Nat Commun, 2022, 13(1):4229
J Mol Cell Cardiol, 2021, S0022-2828(21)00246-7
S4102 Eprosartan Mesylate Eprosartan(SKF-108566J) is a nonpeptide angiotensin II receptor antagonist, [3H]-eprosartan binds to the AT1 receptor with KD of 0.83 nM in rat vascular smooth muscle cells.
Eur J Drug Metab Pharmacokinet, 2022, 10.1007/s13318-022-00780-x
bioRxiv, 2020, 10.1101/2020.10.13.337774
Sci Rep, 2016, 10.1038/srep25694
S3046 Azilsartan Azilsartan (TAK-536) is an angiotensin II type 1 (AT1) receptor antagonist with IC50 of 2.6 nM.
Front Pharmacol, 2021, 12:774709
bioRxiv, 2020, 10.1101/2020.10.13.337774
Sci Rep, 2015, 5:8116
S1604 Olmesartan Medoxomil Olmesartan Medoxomil (CS-866,RNH-6270) is a selective angiotensin II type 1 (AT(1)) receptor antagonist, used in the treatment of high blood pressure.
Nan Fang Yi Ke Da Xue Xue Bao, 2020, 40(4):499-505
Sci Rep, 2015, 5:8116
S6665 Sparsentan (PS-433540, RE-021) Sparsentan (PS-433540, RE-021, DARA) is a dual endothelin type A receptor(ETA) and angiotensin II type 1 receptor antagonist.
Front Pharmacol, 2022, 13:964370
Biomedicines, 2021, 10(1)86
E0039 A-779

A-779 is a potent and selective antagonist for Angiotensin-(1–7) (Ang-(1-7)) with an IC50 of 0.3 nM in a radioligand binding assay. A-779 shows no significant affinity for AT1 or AT2 receptors at a concentration of 1 μM.

Int J Biol Sci, 2023, 19(8):2613-2629
Elife, 2022, 11e72266
S3057 Azilsartan Medoxomil Azilsartan Medoxomil (TAK-491) is a potent angiotensin II type 1 (AT1) receptor antagonist, inhibits the RAAS, with an IC50 of 2.6 nM, exhibits >10,000-fold selectivity over AT2.
Sci Rep, 2015, 5:8116
S5581 Olmesartan Olmesartan (RNH-6270) is an an angiotensin 2 receptor antagonist with antihypertensive activity.
bioRxiv, 2020, 10.1101/2020.10.13.337774
S4975 Fimasartan Fimasartan (Kanarb) is a non-peptide angiotensin II receptor antagonist (ARB) with noncompetitive, insurmountable binding with the AT1 receptor. It is used for the treatment of hypertension and heart failure.
Drug Metab Dispos, 2020, 48(12):1264-1270
S0326 Olodanrigan (EMA401) Olodanrigan (EMA401, PD-126055, (S) PD-126055) is a highly selective, orally active, peripherally restricted antagonist of angiotensin II type 2 receptor (AT2R). Olodanrigan (EMA401) analgesic action appears to involve the inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons.
S5980 Losartan Carboxylic Acid (EXP-3174) Losartan Carboxylic Acid (E-3174, EXP-3174), an active carboxylic acid metabolite of Losartan, is a non-peptide angiotensin II (AT1) receptor antagonist. Losartan Carboxylic Acid inhibits the specific binding of [125I]-angiotensin II to VSMC with IC50 of 1.1 nM.

Choose Selective Angiotensin Receptor Inhibitors

Tags: Angiotensin Receptor inhibitor|Angiotensin Receptor agonist|Angiotensin Receptor activator|Angiotensin Receptor inducer|Angiotensin Receptor antagonist|Angiotensin Receptor signaling pathway|Angiotensin Receptor assay kit